Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Robert Reiter
University of California Los Angeles, Department: Biochemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
ImaginAB Inc
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution
Professor Reiter has disclosed financial interests in ImaginAB, Inc., a privately held company. He is a co-founder, Chief Medical Advisor and owns company stock valued at (b)(4). He is also a co-inventor of “Engineered Anti-Prostate Stem Cell Antigen (PSCA) Antibodies for Cancer Targeting” which will be further developed in this project. The IP has been licensed it to ImaginAB, Inc and is owned by The Regents. The Regents took equity in the licensing transaction with ImaginAB. Professor Reiter states that the research will be conducted independently by their laboratories and that every effort will be taken to assure that these projects are conducted independently and free of conflict with ImaginAb.
Multifunctional immunoPET tracers for pancreatic and prostate cancer
Prostate and pancreatic cancers are among the most common and difficult to treat cancers, with major challenges in accurately diagnosing and staging disease, as well as monitoring response to therapy. One major barrier to progress is the absence of effective molecular imaging tracers/tools that can guide patient management. Here we propose to develop novel cancer-specific molecular imaging agents based on engineered antibodies that recognize PSCA, a cell surface biomarker expressed in pancreatic and prostate cancer, to provide a disease-specific approach for imaging in newly diagnosed and recurrent disease, and to stratify patients at the molecular level in order to guide the use of both traditioal and targeted therapies.
Filed on June 12, 2013.
Tell us what you know about Robert Reiter's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Robert Reiter filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Robert Reiter | University of California Los Angeles | Conflict of Interest | ImaginAB Inc | $550,000 - $599,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.